Incyte (NASDAQ:INCY) has been given a $145.00 price target by investment analysts at Credit Suisse Group in a report released on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective suggests a potential upside of 64.46% from the company’s previous close.

Several other analysts have also weighed in on INCY. Nomura reissued a “buy” rating on shares of Incyte in a report on Thursday, February 1st. BidaskClub lowered Incyte from a “sell” rating to a “strong sell” rating in a report on Thursday, February 1st. Oppenheimer set a $120.00 target price on Incyte and gave the company a “hold” rating in a report on Tuesday, January 2nd. TheStreet lowered Incyte from a “c-” rating to a “d+” rating in a report on Tuesday, December 5th. Finally, Cowen reissued a “buy” rating on shares of Incyte in a report on Tuesday, December 5th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Incyte presently has an average rating of “Buy” and an average price target of $142.94.

Shares of Incyte (NASDAQ:INCY) opened at $88.17 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. The firm has a market capitalization of $18,577.61, a price-to-earnings ratio of -110.21 and a beta of 0.59. Incyte has a twelve month low of $80.85 and a twelve month high of $153.15.

In related news, insider David W. Gryska sold 6,760 shares of the stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $98.87, for a total transaction of $668,361.20. Following the transaction, the insider now directly owns 20,752 shares in the company, valued at $2,051,750.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Vijay K. Iyengar sold 5,000 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $97.26, for a total value of $486,300.00. The disclosure for this sale can be found here. Insiders have sold 12,456 shares of company stock worth $1,222,876 over the last quarter. 17.70% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Financial Gravity Companies Inc. purchased a new position in Incyte during the fourth quarter worth about $120,000. Private Advisor Group LLC purchased a new position in Incyte during the third quarter worth about $203,000. Advantage Investment Management LLC lifted its position in Incyte by 1,233.3% during the fourth quarter. Advantage Investment Management LLC now owns 2,000 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 1,850 shares during the period. Caxton Associates LP purchased a new position in Incyte during the third quarter worth about $257,000. Finally, Mission Wealth Management LP purchased a new position in Incyte during the fourth quarter worth about $213,000. Hedge funds and other institutional investors own 90.02% of the company’s stock.

WARNING: This report was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2018/02/15/incyte-incy-pt-set-at-145-00-by-credit-suisse-group.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.